Recent

% | $
Quotes you view appear here for quick access.

Antares Pharma Inc. Message Board

  • junkyarddogbarking junkyarddogbarking Nov 8, 2013 8:17 AM Flag

    NorvoNordisc FlexPen commercials will Help ATRS win

    They are making people aware of how easy and actually dare I say stylish it is to use.
    They also stress that insurance covers it !
    Every time I see one of those commercials I smile knowing they are paving the way for ATRS

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • junkdog: That makes sense to me. The TEVA / ATRS Pen 1 & 2, we know from Antares that the combined revenues are in the range of $1.5 Billion dollars.

      I posted this prior: "Go to ihub and look at my post # 2389. I believe TEVA / ATRS Pen #1 could very well be an insulin drug.
      Check out the company Novo Nordisk. Whatever it is, we know from Antares, that it is a aNDA filing. And when it's filed it will trigger a patent infringement by the drugs holder more than likely and then a 30 month stay. Just like TEVA v King and the epi-pen fun and games. The drug for Pen #1 is definitely not a generic drug. In 2003, Antares had a deal with Eli Lilly for a diabetic drug. Never came to fruition. I think that is what nammuang is referring to"

      Sentiment: Strong Buy

      • 1 Reply to jab91252
      • If we're trying to enter the insulin pen market then all I've got to say is good luck unless we have some prior patents since ATRS was one of the initial developers of an insulin injector.

        I imagine the patents on the Flexpen protects them for another 20 yrs. Its the same thing we're doing with Otrexup to block competition.

 
ATRS
1.26+0.08(+6.78%)Aug 30 4:00 PMEDT